Since accepted in 2014, tucidinostat was considered as a next-line and subsequent therapy for PTCL people in China. Medical trials and preclinical reports in numerous hematological malignancies and strong tumors is in development. Numerous ongoing medical investigations study tucidinostat use in several mixtures for relapsed and newly diagnosed PTCL (Tables https://rotenone55432.ja-blog.com/29943003/helping-the-others-realize-the-advantages-of-dmpo